U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07209761) titled 'A Study of Quabodepistat-containing Regimen for the Treatment of Drug-resistant Pulmonary Tuberculosis' on Aug. 12.
Brief Summary: This study aims to assess quabodepistat-based treatment regimen for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drugs, can shorten treatment duration to 4 months and be as effective and safer than current WHO endorsed treatment regimen given for 6-months. The study will compare different drug combinations in two groups of patients: those whose T...